Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Gastroenterology | Family Medicine

Crohn's Disease Clinical Trials


A listing of Crohn's Disease medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Birmingham : Achieve Clinical Research, LLC an Accel Research Site

A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and efficacy of AMG 181 in subjects with Moderate to Severe Crohn's Disease

View More »

Birmingham : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Mobile :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Arizona

Goodyear : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Little Rock : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Phoenix :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Scottsdale : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Scottsdale : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

View More »

Tucson : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Tucson : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tucson :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tucson :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tucson : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Tucson : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Tucson : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Arkansas

Little Rock : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Little Rock : Preferred Research Partners Inc

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Little Rock : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Little Rock : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

California

Corona : TRIMED Clinical Trials

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Glendale : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

La Jolla :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

La Jolla :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

La Jolla : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

View More »

La Jolla : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

La Jolla : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

La Jolla : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Laguna Hills : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Los Angeles :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Los Angeles : Cedars Sinai Medical Center Updated

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Los Angeles :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Los Angeles :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oakland :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Orange : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Orange : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

San Carlos : Digestive Care Associates, LLC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

San Carlos :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

San Diego :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

San Diego :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

San Diego :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

San Diego : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

San Diego : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

San Diego : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

San Francisco :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

San Francisco : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

San Francisco : University of California, San Francisco

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

San Francisco : University of California, San Francisco

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

San Francisco : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

San Francisco : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Colorado

Denver : Rocky Mountain Clinical Research

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Daikenchuto (TU-100) in Subjects with Moderate Crohn’s Disease

View More »

Aurora : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Denver :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Denver : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Denver : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Lafayette : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Lakewood : Rocky Mountain Gastroenterology Associates

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Lakewood : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lakewood : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Lakewood : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Littleton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Littleton : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Littleton : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Lone Tree :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lone Tree :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Thornton : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Thornton : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Connecticut

Hamden : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hamden : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hamden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hartford :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New Haven :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

View More »

New Haven :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

District of Columbia

Washington : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Washington : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Florida

Clearwater : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Clearwater : Clinical Research of West Florida, Inc

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Clearwater : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Clearwater : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Clearwater : Clinical Research of West Florida

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

View More »

Clearwater : Clinical Research of West Florida

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Crystal River : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Crystal River : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Gainesville :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Gainesville : University of Florida Updated

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Gainesville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Gainesville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Inverness : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Inverness : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Jacksonville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Jacksonville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Jacksonville : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Largo : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Largo : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Miami :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Miami : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Miami : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Miami : Jackson Memorial Hospital

Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease

Miami : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Miami : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Naples : Gastroenterology Group of Naples

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Naples :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Naples :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

New Port Richey : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Orlando :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Orlando : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Orlando : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Port Orange : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Sanford : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Sanford : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Trinity : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Weston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Winter Park : Shafran Gastroenterology Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Winter Park :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Winter Park :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Winter Park : Shafran Gastroenterology Center

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

Winter Park : Shafran Gastroenterology Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Winter Park : Shafran Gastroenterology Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Winter Park : Shafran Gasteroenterology Center

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Georgia

Atlanta :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Atlanta : Atlanta Gastroenterology Associates, LLC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Atlanta :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Atlanta :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Atlanta : Atlanta Gastroenterology Associates

Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients

View More »

Atlanta : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Atlanta : Atlanta Gastroenterology Associates

Optimizing Cimzia in Crohn's Patients

Atlanta : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Atlanta : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Decatur : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Decatur :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Decatur :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Decatur : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Macon : Gastroenterology Associates of Central Georgia, LLC Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Macon : Gastroenterology Associates of Central Georgia

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Macon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Macon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Macon : Gastroenterology Associates of Central Georgia, LLC Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Marietta : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Marietta : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Idaho

Boise :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Illinois

Arlington Heights : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Arlington Heights : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Chicago :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Chicago : University of Chicago Hospital Medical Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chicago : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

View More »

Chicago :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chicago : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Chicago : University of Chicago Medical Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Chicago : University of Chicago

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chicago : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chicago : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Evanston : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Evanston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Glenview : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Oak Lawn : Southwest Gastroenterology Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Indiana

Indianapolis : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Indianapolis : IU School of Medicine - Gastroenterology

PillCam® Platform With the PillCam Crohn's Disease Capsule

Iowa

Clive :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Clive :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Clive : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Kansas

Pratt :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pratt :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Topeka : Cotton-O'Neil Clinical Research Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Topeka : Cotton-O'Neil Clinical Research Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Kentucky

Lexington : University of Kentucky Chandler Medical Center

Crohn’s Disease Research Study

View More »

Crestview Hills :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Crestview Hills :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lexington : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lexington :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lexington :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lexington : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Lexington : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Louisville : University of Louisville School of Medicine

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Louisville : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Louisiana

Baton Rouge :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Baton Rouge :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hammond : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hammond : Gastroenterology Research Of New Orleans

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Hammond : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

View More »

Monroe : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Monroe : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

New Orleans :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New Orleans :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

New Orleans :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Maine

Portland :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Maryland

Chevy Chase : MGG Group Co., Inc., Chevy Chase Clinical Research

Ulcerative Colitis and Crohn’s Disease (IBD) Research Study

View More »

Annapolis : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Annapolis : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Baltimore :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Baltimore : University of Maryland, Baltimore

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Baltimore : University of Maryland, Baltimore

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group. PC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chevy Chase :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chevy Chase :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chevy Chase : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Chevy Chase : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Chevy Chase : Chevy Chase Clinical Research

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Chevy Chase : Chevy Chase Clinical Research

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Chevy Chase : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chevy Chase : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Towson : Endoscopic Microsurgery Associates PA

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Towson :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Towson :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Towson : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Massachusetts

Boston :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Boston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Boston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Boston : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Boston : Boston Medical Center

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients

View More »

Boston : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Boston : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Boston : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Brockton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Newton : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Quincy : MedRACS

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Worcester :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Worcester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Worcester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Worcester : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Worcester : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Michigan

Ann Arbor : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Ann Arbor :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ann Arbor :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Ann Arbor : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Ann Arbor : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

View More »

Chesterfield : Clinical Research Institute of Michigan

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chesterfield :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chesterfield :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chesterfield : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Chesterfield : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Chesterfield : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Chesterfield : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Detroit :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Grand Rapids : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Novi :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Novi :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Troy : Center for Digestive Health Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Troy : Center for Digestive Health

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Troy :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Troy :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Troy : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Troy : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Troy : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Troy : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Wyoming : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Ypsilanti : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Ypsilanti :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ypsilanti :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Ypsilanti : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Minnesota

Minneapolis :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Rochester :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Rochester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Rochester : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Rochester : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

View More »

Rochester : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Saint Paul :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

St. Paul : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

St. Paul : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Mississippi

Ocean Springs : Digestive Health Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Ocean Springs :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ocean Springs :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Missouri

St. Louis : Washington University in St. Louis - Center for Clinical Studies

Washington University seeks healthy volunteers and patients with Crohn’s disease for a research study.

View More »

Columbia : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Columbia : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Jefferson City : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Kansas City : The Children's Mercy Hospital

Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease

Lee's Summit :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lee's Summit :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lee's Summit : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Mexico :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Mexico : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Mexico : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Mexico : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Mexico : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

St. Louis : St. Louis Center for Clinical Research

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

St. Louis : St Louis Center for Clinical Studies

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

St. Louis : Saint Louis Center for Clinical Research

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Studies

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

St. Louis : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Nebraska

Boys Town :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Nevada

Las Vegas :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Las Vegas :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

New Hampshire

Lebanon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Manchester :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New Jersey

Berlin : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Egg Harbor Township :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Marlton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Marlton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Mays Landing :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

View More »

Mays Landing : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Mays Landing : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Morristown :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Morristown : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Morristown : Research Site

Safety Study of Entocort for Children With Crohn's Disease

New York

New York : Manhattan Medical Research

A New Approach to Crohn's Disease Treatment

View More »

Albany : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Albany : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Brooklyn :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Brooklyn : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Buffalo :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Buffalo : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Buffalo : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Great Neck : Long Island Clinical Research Associates, LLP

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Great Neck :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Great Neck :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Great Neck : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Great Neck : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Great Neck : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Great Neck : Nyu Langone Long Island Clinical Research Associates

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Great Neck : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Great Neck : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Hollis : NY Scientific CORP

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Lake Success : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Lake Success : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Mineola :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New Hyde Park :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New York :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New York : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

New York :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

New York :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

New York : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

New York : Hospital

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

New York : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

New York : Weill Cornell Medical College

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

New York : Mount Sinai School of Medicine

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

New York : Mount Sinai School of Medicine

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

New York : Weill Cornell Medical College

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

New York : Mount Sinai School Of Medicine

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Poughkeepsie : Premier Medical Group of the Hudson Valley, PC Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Poughkeepsie : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Poughkeepsie : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Rochester : Rochester General Hospital Updated

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Rochester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Stony Brook :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Stony Brook : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Syracuse :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

North Carolina

Charlotte : Piedmont Medical Research

Crohn's Disease Study

Charlotte : PMG Research of Charlotte

Crohn's Disease Study

Raleigh : Wake Research Associates

Treating your Crohn's disease doesn't have to be a solo act.

Salisbury : PMG Research of Salisbury

Is Crohn’s Disease part of your daily life?

Winston-Salem : PMG Research of Winston-Salem

Is Crohn’s Disease part of your daily life?

View More »

Chapel Hill :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Chapel Hill :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chapel Hill :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chapel Hill : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Chapel Hill : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Chapel Hill : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chapel Hill : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Charlotte :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Charlotte :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Charlotte : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Charlotte : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Charlotte : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Durham :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Durham : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Greenville : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Raleigh :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Raleigh :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Raleigh : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Raleigh : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Salisbury : PMG Research of Salisbury

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Winston-Salem : PMG Research of Winston-Salem, LLC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Ohio

Beavercreek : Dayton Gastroenterology

Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients

Cincinnati : Consultants for Clinical Research

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Cincinnati : Ohio Gastroenterology and Liver

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Cincinnati :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Cincinnati :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

View More »

Cincinnati : Consultants For Clinical Research

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Cleveland :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Columbus : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Columbus : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Columbus : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Mentor : Great Lakes Gastroenterology Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Mentor : The Endoscopy Center of Lake County Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Mentor : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Mentor : Great Lakes Gastroenterology Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Oklahoma

Norman :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oklahoma City :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Oklahoma City : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Oklahoma City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oklahoma City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

View More »

Oklahoma City : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Oklahoma City : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Tulsa : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tulsa : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Tulsa : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tulsa : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Oregon

Eugene : Clinical Trials of America, Inc

Are you a man or woman over 18, with moderate to severe, active Crohn’s Disease?

View More »

Bend :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bend :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Portland : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Portland : Oregon Health & Science University

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

Portland : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Pennsylvania

Danville :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Hershey :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hershey : Penn State Milton S. Hershey Medical Center

Cimzia Versus Mesalamine for Crohn's Recurrence

King of Prussia : Omnicare Clinical Research, Inc.

Phase II Study of HMPL-004 in Subjects With Crohn's Disease

Philadelphia :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

View More »

Philadelphia :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Philadelphia :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Philadelphia : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Pittsburgh : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Pittsburgh :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Pittsburgh : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Pittsburgh : Children's Hospital of Pittsburgh of UPMC

Autologous Stem Cell Transplantation for Crohn's Disease

Pittsburgh : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Pittsburgh : University of Pittsburgh

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

South Carolina

Greenville :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

North Charleston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

North Charleston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tennessee

Jackson : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Knoxville :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Memphis :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Nashville : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Nashville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

View More »

Nashville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Nashville : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Nashville : Inflammatory Bowel Disease Clinic c/o Divison of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, Vanderbilt University

Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use

Nashville : Vanderbilt University Medical Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Nashville : Vanderbilt University Medical Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Nashville : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Nashville : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Nashville : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Texas

Austin : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Austin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Austin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Austin : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Dallas :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

View More »

Dallas : Dallas VA Medical Center

Exacerbating Factors in Inflammatory Bowel Disease

Fort Worth :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Grapevine :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Grapevine :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Houston : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Houston : Baylor College of Medicine Updated

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Houston : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Houston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Houston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Houston : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Pasadena : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

San Antonio : Gastroenterology Research Of San Antonio

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Southlake : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Sugar Land : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tyler : Endoscopy Center of Tyler Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Tyler : Digestive Health Specialists of Tyler Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Tyler :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tyler :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tyler : Endoscopy Center of Tyler Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Tyler : Digestive Health Specialists of Tyler Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Utah

Ogden : Advanced Research Institute

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Ogden : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Ogden : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Ogden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Salt Lake City : University of Utah

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

View More »

Salt Lake City : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Salt Lake City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Salt Lake City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Salt Lake City : University of Utah HSC Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Salt Lake City : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Vermont

Burlington :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Virginia

Charlottesville :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Charlottesville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chesapeake :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chesapeake :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Christiansburg : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

View More »

Christiansburg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Christiansburg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Danville : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Danville : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Danville : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Fairfax :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Norfolk :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Norfolk : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Norfolk : Gastrointestinal and Liver Specialists Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Richmond : McGuire VA Medical Center Updated

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Richmond : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Richmond : McGuire Research Institute

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Richmond : McGuire Research Institute

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Richmond : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Virginia Beach :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Virginia Beach :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Washington

Seattle :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Seattle : University of Washington Medical Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Seattle :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Seattle :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Seattle : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

View More »

Seattle : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Seattle : University of Washington Medical Center

Induction of Clinical Response Using Rifaximin in Crohn's Disease

Seattle : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Seattle : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

West Virginia

Morgantown : United BioSource Corporation

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

Wisconsin

Madison :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Madison :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Madison :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Madison : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Madison : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

View More »

Milwaukee :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Milwaukee : Wisconsin Center for Advanced Research - GI Associates, LLC Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Milwaukee : The Center for Digestive Health Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Milwaukee : Wisconsin Center for Advanced Research - GI Associates, LLC Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Milwaukee : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Milwaukee : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Milwaukee : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Milwaukee : Wisconsin Center for Advanced Research - GI Associates, LLC Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Wauwatosa : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Wauwatosa : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Australia

Adelaide :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Adelaide : Royal Adelaide Hospital

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Adelaide : Royal Adelaide Hospital

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Adelaide : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Adelaide : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

View More »

Adelaide : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Adelaide : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Bankstown : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bankstown : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Bedford Park :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Box Hill :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Brisbane : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Brisbane : QPharm

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease

Cairns :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Central Queensland M C :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Central Queensland M C :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Concord :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Concord :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Fitzroy : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fitzroy : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Fremantle :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Fremantle : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Fremantle : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fremantle : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Garran :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Garran :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hersten : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hersten : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Herston : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Herston : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Kingswood : Nepean Hospital Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Kingswood : Nepean Hospital Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Liverpool :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Liverpool :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Malvern :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Malvern :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Melbourne : Royal Melbourne Hospital

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Melbourne : Royal Melbourne Hospital

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Melbourne : Center for Clinical Studies

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease

Parkville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Parkville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Parkville : Monash Medical Centre Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Prahran : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Prahran : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Prahran : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

South Brisbane : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

South Brisbane : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Austria

Innsbruck :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oberpullendorf : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Oberpullendorf : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Oberpullendorf : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

St. Poelten : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

View More »

St. Veit/Glan : Krankenhaus

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

St.Veit/Glan : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Vienna : Site Reference ID/Investigator# 38145

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Wien :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Wien : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Wien : Medizinische Universität

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Wien : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Wien : Pfizer Investigational Site Updated

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Wien : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Wien : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Wien : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Belgium

Antwerp : UZ Antwerpen

Switching From Adalimumab to Infliximab

Belgium : Belgium

A Study of TRK-170 for the Treatment of Crohn's Disease

Bonheiden : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Bonheiden : Site Reference ID/Investigator# 38147

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Bonheiden : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

View More »

Bonheiden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Brussel :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Brussel :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Brussel : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Brussels : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Brussels : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Brussels : Site Reference ID/Investigator# 38149

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Brussels : Pfizer Investigational Site Updated

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Brussels : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Brussels : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Bruxelles : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Edegem : Site Reference ID/Investigator# 43966

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Genk : Hospital Oost-Limburg

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Gent : Gent University Hospital

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Gent : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Gent : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Gent : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Ghent : University Hospital Ghent

Switching From Adalimumab to Infliximab

Hasselt : Virga Jesse hospital

Switching From Adalimumab to Infliximab

Kortrijk : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Kortrijk : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Kortrijk : AZ Groeninge

Switching From Adalimumab to Infliximab

Leuven :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Leuven :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Leuven : Leuven University Hospital

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Leuven : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Leuven : Site Reference ID/Investigator# 38151

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Leuven : Pfizer Investigational Site Updated

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Leuven : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Leuven : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Leuven : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Leuven : UZ Leuven

Switching From Adalimumab to Infliximab

Liege :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Liege : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Liege : Site Reference ID/Investigator# 38150

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Liege : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Mouscron : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Mouscron : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Oostende : AZ Damiaan

Switching From Adalimumab to Infliximab

Ottignies : Clinique Saint-Pierre

Switching From Adalimumab to Infliximab

Roeselare : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Roeselare : Hospital Hartziekenhuis

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Roeselare : Site Reference ID/Investigator# 38146

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Roeselare : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Roeselare : Heilig Hartziekenhuis Roeselare

Switching From Adalimumab to Infliximab

Brazil

Curitiba : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Curitiba : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Goiania : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Goiás :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ilha do Fundao - Rio de Janeiro : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

View More »

Porto Alegre : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Porto Alegre :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Porto Alegre :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Rio de Janeiro : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Rio De Janeiro :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rio De Janeiro :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sao Paulo : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Sao Paulo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

São Paulo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bulgaria

Bulgaria : Bulgaria

A Study of TRK-170 for the Treatment of Crohn's Disease

Pleven :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pleven :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Rousse :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rousse :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

View More »

Sofia :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sofia :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sofia : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Varna :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Varna :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Canada

Brandon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Brandon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Calgary : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Calgary :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Calgary :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

View More »

Calgary : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Calgary : Site Reference ID/Investigator# 38156

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Calgary : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Calgary : Division of Gastroenterology

Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)

Calgary : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Edmonton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Edmonton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Edmonton : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Edmonton : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Halifax : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Halifax : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Halifax : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Halifax : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Hamilton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hamilton : Site Reference ID/Investigator# 45062

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Hamilton : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Kingston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kingston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

London : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

London :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

London :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

London : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

London : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

London : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

London : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

London : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Montreal : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Montreal :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Montreal :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Montreal : Hopital Maisonneuve-Rosemont Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Montreal : Innovaderm Research Inc.

Adalimumab-psoriasis and Small Bowel Lesions

Montreal : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Montreal : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Montreal : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Oshawa : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Ottawa : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Quebec : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Quebec : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Quebec City : Site Reference ID/Investigator# 38157

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Toronto : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Toronto :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Toronto : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Toronto : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Vancouver :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Vancouver :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Vancouver : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Vancouver : Site Reference ID/Investigator# 45502

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Vancouver : Research Site

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

Vancouver : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Vancouver : Gastrointestinal Research Institute

Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease

Vancouver : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Vaughan : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Vaughan : Site Reference ID/Investigator# 38155

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Vaughan : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Victoria : PerCuro Clinical Research Limited Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Victoria : Office of Dr. David C. Pearson Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Victoria : Office of Drs Ranjit A. Singh, Jamie D. Papp Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Victoria : Office of Drs. Ranjith Andrew Singh and Jamie D. Papp Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Victoria : PerCuro Clinical Research Limited Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Victoria : Office of Dr. David C. Pearson Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Winnipeg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Winnipeg : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Winnipeg : Site Reference ID/Investigator# 38152

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Winnipeg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Croatia

Avenija Gojka Suska 6 :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Osijek :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rijeka :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rijeka :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Zagreb :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Czech Republic

Czech Republic : Czech Republic

A Study of TRK-170 for the Treatment of Crohn's Disease

Hradec Kralove :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hradec Kralove : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Hradec Králové : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hradec Králové : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

View More »

Hradec Kralove 12 : Site Reference ID/Investigator# 38159

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Olomouc :

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Olomouc : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Olomouc : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Ostrava - Vitkovice : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Prague 7 : Site Reference ID/Investigator# 38158

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Praha 10 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Praha 4 : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Praha 4 : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Praha 4 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Praha 7 : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Praha 7 : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Praha 7 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Praha 9 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Usti nad Labem : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Usti Nad Labem :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Usti nad Labem : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Denmark

Aalborg : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Aalborg : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Aalborg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aalborg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Aarhus : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

View More »

Aarhus : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aarhus : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Aarhus C : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Herlev : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Herlev :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Herlev : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Herlev : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Herlev : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Herlev : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Herlev : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hilleroed : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hilleroed : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Hvidovre : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hvidovre : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Hvidovre : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Hvidovre : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hvidovre : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Køge : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Koebenhavn : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Koebenhavn : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Koebenhavn NV : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Koebenhavn NV : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Koege : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Koege : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Odense : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Odense : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Odense C : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Silkeborg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Estonia

Tallinn : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Tallinn : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tartu : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Tartu : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tartu : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

France

Amiens :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Amiens : Site Reference ID/Investigator# 38164

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amiens CEDEX 01 : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Amiens Cedex 1 :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Amiens Cedex 1 : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

View More »

Bordeaux :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bordeaux cedex : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Caen Cedex 9 :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Clichy : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Clichy cedex : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Clichy cedex : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Clichy Cedex : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

France : France

A Study of TRK-170 for the Treatment of Crohn's Disease

Lille :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lille Cedex : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lille Cedex : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Lille Cedex : Site Reference ID/Investigator# 38163

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lille cedex : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Marseille :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Marseilles Cedex 20 : Site Reference ID/Investigator# 64742

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Nice : Site Reference ID/Investigator# 42839

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Nice : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

NICE Cedex 3 : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Paris :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Paris :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Paris : Hôpital Necker Enfants Malades, Faculté de Médecine Necker, INSERM EMI0212

Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis

Paris Cedex 10 : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Paris Cedex 10 : Site Reference ID/Investigator# 38165

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Paris cedex 10 : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Paris cedex 10 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Paris Cedex 12 : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Paris Cedex 12 : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Pessac :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Pessac : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Pessac Cedex : Site Reference ID/Investigator# 42818

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Reims :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Rouen :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Rouen : Site Reference ID/Investigator# 43222

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Rouen : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Saint-Priest en Jarez : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Saint-Priest en Jarez : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

St Priest En Jarez : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Toulouse :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Vandoeuvre Les Nancy : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Vandoeuvre Les Nancy :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Vandoeuvre Les Nancy :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Vandoeuvre Les Nancy : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Vandoeuvre Les Nancy : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Vandoeuvre les Nancy Cedex : Site Reference ID/Investigator# 66182

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Germany

Aachen : Site Reference ID/Investigator# 58770

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Aichhalden : Site Reference ID/Investigator# 91100

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Altenburg : Site Reference ID/Investigator# 48900

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Altenholz : Site Reference ID/Investigator# 64006

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Alzey : Site Reference ID/Investigator# 35047

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

View More »

Augsburg : Site Reference ID/Investigator# 35062

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Berka : Site Reference ID/Investigator# 48899

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Homburg : Site Reference ID/Investigator# 58751

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Homburg : Site Reference ID/Investigator# 67702

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Lausick : Site Reference ID/Investigator# 48888

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Salzungen : Site Reference ID/Investigator# 53216

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Wildungen : Site Reference ID/Investigator# 73842

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Baden-Baden : Site Reference ID/Investigator# 73847

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Baden-Baden : Site Reference ID/Investigator# 91099

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bayreuth : Site Reference ID/Investigator# 53217

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bayreuth : Site Reference ID/Investigator# 33443

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Berlin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Berlin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Berlin : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Berlin : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Berlin : Site Reference ID/Investigator# 34240

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33698

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 58758

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33684

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33701

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 48883

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33699

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 34248

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33645

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33700

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33663

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33706

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 34242

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 91101

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 58749

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33455

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 6070

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 34244

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33679

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 73846

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 58764

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33671

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Pfizer Investigational Site Updated

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Berlin : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Berlin : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Berlin : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Bernau : Site Reference ID/Investigator# 73834

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Biberach : Site Reference ID/Investigator# 105656

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bielefeld : Site Reference ID/Investigator# 34278

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bitburg : Site Reference ID/Investigator# 73835

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bitterfeld : Site Reference ID/Investigator# 34281

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bochum :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bochum : Site Reference ID/Investigator# 58765

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bonn : Site Reference ID/Investigator# 73843

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bonn : Site Reference ID/Investigator# 53273

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bonn : Site Reference ID/Investigator# 53237

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bonn : Site Reference ID/Investigator# 53253

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Brandenburg : Site Reference ID/Investigator# 34304

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Braunschweig : Klinikum Braunscheweig

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Braunschweig : Site Reference ID/Investigator# 35654

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bremen : Site Reference ID/Investigator# 48902

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bremerhaven : Site Reference ID/Investigator# 105638

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bremervoerde : Site Reference ID/Investigator# 34690

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Buchholz : Site Reference ID/Investigator# 48884

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Buende : Site Reference ID/Investigator# 34693

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Buende : Site Reference ID/Investigator# 53178

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Burglengenfeld : Site Reference ID/Investigator# 53282

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Chemnitz : Site Reference ID/Investigator# 34702

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Chemnitz : Site Reference ID/Investigator# 34701

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Chemnitz : Site Reference ID/Investigator# 53143

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Coburg : Site Reference ID/Investigator# 34705

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Coesfeld : Site Reference ID/Investigator# 34706

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Coesfeld : Site Reference ID/Investigator# 53152

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Cologne : Site Reference ID/Investigator# 53124

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Cottbus : Site Reference ID/Investigator# 34713

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Cottbus : Site Reference ID/Investigator# 53342

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Cottbus : Site Reference ID/Investigator# 34714

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dachau : Site Reference ID/Investigator# 53285

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Darmstadt : Site Reference ID/Investigator# 35624

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Darmstadt : Site Reference ID/Investigator# 34719

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Darmstadt : Site Reference ID/Investigator# 35623

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Darmstadt : Site Reference ID/Investigator# 53157

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Datteln : Site Reference ID/Investigator# 34721

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Detmold : Site Reference ID/Investigator# 58776

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dingolfing : Site Reference ID/Investigator# 34732

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dinkelsbuehl : Site Reference ID/Investigator# 34733

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dippoldiswalde : Site Reference ID/Investigator# 34735

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dortmund : Site Reference ID/Investigator# 34743

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dresden : Site Reference ID/Investigator# 34757

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dresden : Site Reference ID/Investigator# 35638

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dresden : Site Reference ID/Investigator# 73841

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dresden : Site Reference ID/Investigator# 34745

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dresden : Site Reference ID/Investigator# 34761

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Duesseldorf : Site Reference ID/Investigator# 34770

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ebern : Site Reference ID/Investigator# 48895

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Eichstaett : Site Reference ID/Investigator# 99800

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Eisenach : Site Reference ID/Investigator# 48898

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ellefeld : Site Reference ID/Investigator# 34791

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Emden : Site Reference ID/Investigator# 34798

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Erfurt : Site Reference ID/Investigator# 34806

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Erlangen :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Erlangen : Site Reference ID/Investigator# 35192

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Erlangen : Site Reference ID/Investigator# 34818

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Erlangen : Site Reference ID/Investigator# 34819

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Erlangen : Department of Medicine I, University of Erlangen-Nuremberg

Endomicroscopy in IBD Patients

Eschweiler : Site Reference ID/Investigator# 34822

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Essen : Site Reference ID/Investigator# 34826

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Essen : Site Reference ID/Investigator# 91102

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Essen : Site Reference ID/Investigator# 53168

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Euskirchen : Site Reference ID/Investigator# 53165

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Frankfurt : Site Reference ID/Investigator# 34835

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Frankfurt : Site Reference ID/Investigator# 34850

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Frankfurt : Site Reference ID/Investigator# 34836

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Frankfurt Am Main :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Frankfurt Am Main :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Frankfurt am Main : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Frankfurt am Main : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Frankfurt/Main : Klinikum Frankfurt

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Freiburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Freiburg : Site Reference ID/Investigator# 34862

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Freiburg : Site Reference ID/Investigator# 34858

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Freital : Site Reference ID/Investigator# 34864

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Fuerth : Site Reference ID/Investigator# 34869

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Garbsen : Site Reference ID/Investigator# 34874

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Gardelegen : Site Reference ID/Investigator# 34875

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Garmisch-Partenkirchen : Site Reference ID/Investigator# 34876

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Gedern : Site Reference ID/Investigator# 73844

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Germering : Site Reference ID/Investigator# 99801

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Gifhorn : Site Reference ID/Investigator# 58750

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Gilching : Site Reference ID/Investigator# 53202

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Goeda : Site Reference ID/Investigator# 34891

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Goerlitz : Site Reference ID/Investigator# 34892

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Goettingen : Site Reference ID/Investigator# 73845

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Grevenbroich : Site Reference ID/Investigator# 53204

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Gruenstadt : Site Reference ID/Investigator# 34909

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hagen : Site Reference ID/Investigator# 34915

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Halle :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Halle : Site Reference ID/Investigator# 34927

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 34916

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 99807

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 58756

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 34934

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 99798

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 34933

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle (Saale) : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Hamburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hamburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hamburg : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Hamburg : Site Reference ID/Investigator# 35108

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34987

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34948

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34976

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 58767

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 58742

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 58772

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 35439

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34990

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34978

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34979

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 35002

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 105655

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 99802

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34975

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 58763

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 73837

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hamburg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hameln : Site Reference ID/Investigator# 35013

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamm : Site Reference ID/Investigator# 99806

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamm : Site Reference ID/Investigator# 35016

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hannover :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hannover :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hannover : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Hannover : Site Reference ID/Investigator# 33787

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hannover : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hannover : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hanover : Site Reference ID/Investigator# 53145

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hanover : Site Reference ID/Investigator# 35031

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Haßloch :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Haßloch :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hausham : Site Reference ID/Investigator# 67703

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hechingen : Site Reference ID/Investigator# 67705

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Heidelberg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Heidelberg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Heidelberg : Site Reference ID/Investigator# 48885

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Heidelberg : Site Reference ID/Investigator# 33814

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Heidenau : Site Reference ID/Investigator# 81618

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Herne : Site Reference ID/Investigator# 33822

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Herne : Site Reference ID/Investigator# 33821

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hildesheim : Site Reference ID/Investigator# 35473

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hoyerswerda : Site Reference ID/Investigator# 64002

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Illingen : Site Reference ID/Investigator# 81616

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Iserlohn : Site Reference ID/Investigator# 81615

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Jena :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Jena Lebeda Ost : Site Reference ID/Investigator# 33939

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Karlsruhe : Site Reference ID/Investigator# 53162

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kassel : Site Reference ID/Investigator# 35485

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kassel : Site Reference ID/Investigator# 35486

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kiel : Universitaetsklinikum Schleswig-Holstein Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Kiel : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Kiel :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kiel :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Kiel : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Kiel : Site Reference ID/Investigator# 33976

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kiel : Site Reference ID/Investigator# 48901

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kiel : Site Reference ID/Investigator# 33973

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kiel : Site Reference ID/Investigator# 38170

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Kiel : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Kiel : Universitaetsklinikum Schleswig-Holstein Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Kirchheim : Site Reference ID/Investigator# 58773

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kitzingen : Site Reference ID/Investigator# 53149

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Koblenz : Site Reference ID/Investigator# 48903

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Koblenz : Site Reference ID/Investigator# 48897

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Koblenz : Site Reference ID/Investigator# 73836

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Krefeld : Site Reference ID/Investigator# 53275

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Landshut : Site Reference ID/Investigator# 91103

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Lehrte : Site Reference ID/Investigator# 34094

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Leipzig : Site Reference ID/Investigator# 35127

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Leipzig : Site Reference ID/Investigator# 58752

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Leipzig : Site Reference ID/Investigator# 34101

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Leverkusen : Site Reference ID/Investigator# 73833

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Leverkusen : Site Reference ID/Investigator# 58747

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Luebeck : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Luebeck : Site Reference ID/Investigator# 34134

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Luebeck : Site Reference ID/Investigator# 73840

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Luebeck : Site Reference ID/Investigator# 33409

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Luebeck : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Lueneburg : Site Reference ID/Investigator# 34140

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Lÿneburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lÿneburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Magdeburg : Site Reference ID/Investigator# 34151

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Magdeburg : Site Reference ID/Investigator# 38168

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Mainz : Site Reference ID/Investigator# 34153

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Mainz : Site Reference ID/Investigator# 34177

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Malente : Site Reference ID/Investigator# 64004

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Mannheim :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Mannheim :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Mannheim : Site Reference ID/Investigator# 64005

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Mannheim : Site Reference ID/Investigator# 35128

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Mannheim : Site Reference ID/Investigator# 34181

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Marburg : Site Reference ID/Investigator# 48887

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Markkleeberg : Site Reference ID/Investigator# 35130

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Markkleeberg : Site Reference ID/Investigator# 35129

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Meitingen : Site Reference ID/Investigator# 105640

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Meuselwitz : Site Reference ID/Investigator# 48904

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Minden : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Minden :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Minden : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Minden : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Minden : Site Reference ID/Investigator# 34204

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Minden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Minden : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Moenchengladbach : Site Reference ID/Investigator# 53163

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Moenchengladbach : Site Reference ID/Investigator# 53148

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Moers : Site Reference ID/Investigator# 53283

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Moessingen : Site Reference ID/Investigator# 53154

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Muenster : Site Reference ID/Investigator# 48890

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Muenster : Site Reference ID/Investigator# 34045

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Muenster : Site Reference ID/Investigator# 35133

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Muenster : Site Reference ID/Investigator# 99804

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Muenster : Site Reference ID/Investigator# 35301

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munchen : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Munchen : Research Site

Safety Study of Entocort for Children With Crohn's Disease

München :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

München :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Munich : Site Reference ID/Investigator# 99799

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 73839

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 81617

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 99803

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 34033

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 58744

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 53169

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 58754

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 34038

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 91098

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 105637

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Münster :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Münster :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Neubrandenburg : Site Reference ID/Investigator# 35307

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neubrandenburg : Site Reference ID/Investigator# 35308

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neumuenster : Site Reference ID/Investigator# 34069

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neuruppin : Site Reference ID/Investigator# 53172

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neustadt : Site Reference ID/Investigator# 34073

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neuwied : Site Reference ID/Investigator# 58769

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neuwied : Site Reference ID/Investigator# 53159

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Nienburg : Site Reference ID/Investigator# 58759

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Nienburg : Site Reference ID/Investigator# 34156

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Nordhausen : Site Reference ID/Investigator# 34162

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Nuremberg : Site Reference ID/Investigator# 53166

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Nurnberg : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Nurnberg : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Offenburg : Site Reference ID/Investigator# 51866

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Oldenburg : Site Reference ID/Investigator# 33493

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Oldenburg : Site Reference ID/Investigator# 48891

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Oldenburg : Site Reference ID/Investigator# 33494

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Osnabrueck : Site Reference ID/Investigator# 33498

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Osnabrueck : Site Reference ID/Investigator# 35331

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Osnabrueck : Site Reference ID/Investigator# 33500

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Paderborn : Site Reference ID/Investigator# 33501

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Paderborn : Site Reference ID/Investigator# 33502

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Papenburg : Site Reference ID/Investigator# 35337

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Plauen : Site Reference ID/Investigator# 33525

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Potsdam : Site Reference ID/Investigator# 33460

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Potsdam : Site Reference ID/Investigator# 33463

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Radevormwald : Site Reference ID/Investigator# 105639

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Recklinghausen : Site Reference ID/Investigator# 33489

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Regensburg : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Regensburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Regensburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Regensburg : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Regensburg : Site Reference ID/Investigator# 53344

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Regensburg : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Remscheid : Site Reference ID/Investigator# 58761

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Rinteln : Site Reference ID/Investigator# 53142

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Rostock : Site Reference ID/Investigator# 33924

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Rostock : Site Reference ID/Investigator# 48886

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Rottenburg : Site Reference ID/Investigator# 33932

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ruedersdorf : Site Reference ID/Investigator# 34012

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Saarbruecken : Site Reference ID/Investigator# 91113

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Sauerlach : Site Reference ID/Investigator# 91115

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schleswig : Site Reference ID/Investigator# 73838

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schmalkalden : Site Reference ID/Investigator# 34029

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schwalmstadt : Site Reference ID/Investigator# 48892

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schwarz : Site Reference ID/Investigator# 35137

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schweinfurt : Site Reference ID/Investigator# 33545

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schwerin : Site Reference ID/Investigator# 33551

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Solingen : Site Reference ID/Investigator# 58760

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stade :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Stade :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Stade : Site Reference ID/Investigator# 33581

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stade : Site Reference ID/Investigator# 53286

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stade : Site Reference ID/Investigator# 33582

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stralsund : Site Reference ID/Investigator# 33593

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Strausberg : Site Reference ID/Investigator# 48896

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stuhr : Site Reference ID/Investigator# 48894

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stuttgart : Site Reference ID/Investigator# 53263

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stuttgart : Site Reference ID/Investigator# 35385

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stuttgart : Site Reference ID/Investigator# 33612

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stuttgart : Site Reference ID/Investigator# 33599

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Teuchern : Site Reference ID/Investigator# 91114

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Traunstein : Site Reference ID/Investigator# 58753

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Tuebingen : Site Reference ID/Investigator# 33630

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Tutzing : Site Reference ID/Investigator# 73848

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Uelzen : Site Reference ID/Investigator# 48893

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ulm :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ulm :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Ulm : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Ulm : Site Reference ID/Investigator# 33726

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ulm : Site Reference ID/Investigator# 58771

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ulm : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Ulm : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Ulm : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Urbach : Site Reference ID/Investigator# 53164

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Vechta : Site Reference ID/Investigator# 33731

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Vilshofen : Site Reference ID/Investigator# 53251

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Waren : Site Reference ID/Investigator# 33744

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Weilheim : Site Reference ID/Investigator# 53287

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wiesbaden : Site Reference ID/Investigator# 35409

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wiesbaden : Site Reference ID/Investigator# 33763

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wilhelmshaven : Site Reference ID/Investigator# 33769

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Witten : Site Reference ID/Investigator# 67704

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wittenberge : Site Reference ID/Investigator# 53146

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wriezen : Site Reference ID/Investigator# 35083

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wuerselen : Site Reference ID/Investigator# 73849

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wuerselen : Site Reference ID/Investigator# 81619

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wuerzburg : Site Reference ID/Investigator# 99805

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Zittau : Site Reference ID/Investigator# 33868

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Greece

Athens : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Heraklion : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Kolonaki Athens : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hong Kong

Hong Kong : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Hong Kong : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hong Kong : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Shatin, New Territories : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Hungary

Bekescsaba : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Bekescsaba : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Békéscsaba :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Békéscsaba :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Budapest : Fovarosi Onkormanyzat Szent Janos Korhaz es Rendelointezet, I. Belgyogyaszat es Gastroenterologia Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

View More »

Budapest : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Budapest :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Budapest :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Budapest : Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Budapest : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Budapest : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Budapest : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Budapest : Site Reference ID/Investigator# 61053

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Budapest : Site Reference ID/Investigator# 64362

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Budapest : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Budapest : Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Budapest N/A :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Budapest N/A :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Debrecen : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Debrecen : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Debrecen : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Gyongyos : Bugat Pal Korh. Eu-i Szolg. Kozhasznu Nonprofit Kft./Medical Investment Noninvaziv Matrix Belgy. O. Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Gyula :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hungary : Hungary

A Study of TRK-170 for the Treatment of Crohn's Disease

Mosonmagyarovar :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Mosonmagyaróvár :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pecs :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pecs : Site Reference ID/Investigator# 65276

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Szeged : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Szekesfehervar :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Szekesfehervar :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Szeksz Rd N/A :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Szekszard : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Szekszard :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Szekszard : Clinfan Kft. Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Szekszard : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Szekszard : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Szekszard : Clinfan Kft. Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Szekszárd : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Szekszárd : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Szekszárd : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Iceland

Reykjavik :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Reykjavik :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Ireland

Dublin : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Dublin : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Dublin 9 : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Dublin 9 :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Galway : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

View More »

Galway : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Israel

Afula : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Haifa :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Haifa : Site Reference ID/Investigator# 38174

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Holon : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Israel : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

View More »

Israel : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Jerusalem : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Jerusalem :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Jerusalem :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Jerusalem : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Jerusalem : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Jerusalem : Site Reference ID/Investigator# 61275

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Jerusalem : Site Reference ID/Investigator# 61276

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Jerusalem : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Jerusalem : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Kfar Saba : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Kfar Saba :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kfar Saba : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Kfar Saba : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Petach Tikva : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Petach Tikva : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Petach Tikva : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Petah Tikva :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ramat Gan : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Ramat-Gan :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Ramat-Gan : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Rehovot :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rehovot :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tel Aviv : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tel Aviv :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tel Aviv : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Tel Aviv : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Tel Aviv : Site Reference ID/Investigator# 61277

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Tel Aviv : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tel Aviv : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Zerifin : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Italy

Firenze : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Firenze : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Florence : Site Reference ID/Investigator# 46962

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Messina : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Messina : Research Site

Safety Study of Entocort for Children With Crohn's Disease

View More »

Milano : Instituto Clinico Humanitas IRCCS

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Napoli : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Padova : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Roma : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Roma : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Roma : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Roma : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Roma : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Rome : Site Reference ID/Investigator# 38178

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Rome : Site Reference ID/Investigator# 38176

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Rozzano : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Rozzano : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Rozzano : Site Reference ID/Investigator# 38177

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Japan

Aichi : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aichi : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Akita : Site Reference ID/Investigator# 81105

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Bunkyo-ku : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Bunkyo-ku : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

View More »

Chiba : Toho University Sakura Medical Center Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Chiba : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Chiba : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chiba : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Chikushino :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chikushino :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chikushino : Fukuoka University Chikushi Hospital Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Chikushino : Site Reference ID/Investigator# 79700

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Fukuoka :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Fukuoka : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fukuoka : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Fukuoka : Site Reference ID/Investigator# 79643

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Fukuoka : Site Reference ID/Investigator# 79644

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Gifu : Site Reference ID/Investigator# 79694

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hamamatsu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hamamatsu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hamamatsu : Site Reference ID/Investigator# 79645

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hamamatsu : Site Reference ID/Investigator# 79466

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hirosaki : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Hirosaki : Site Reference ID/Investigator# 79642

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hirosaki : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Hiroshima : Site Reference ID/Investigator# 79477

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hokkaido : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hyogo : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hyogo : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Iwafune : Site Reference ID/Investigator# 79681

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kagoshima :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kagoshima :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Kagoshima : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Kagoshima : Site Reference ID/Investigator# 79450

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kanagawa : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Kanagawa : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Kashiwa : Site Reference ID/Investigator# 79478

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kashiwa : Site Reference ID/Investigator# 79675

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kawagoe : Site Reference ID/Investigator# 79693

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Koriyama : Site Reference ID/Investigator# 79454

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kumamoto : Site Reference ID/Investigator# 79445

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kurashiki : Site Reference ID/Investigator# 79636

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kurume : Research Site

Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan

Kyoto : Site Reference ID/Investigator# 79475

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Minato : Site Reference ID/Investigator# 79456

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Minato-ku : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Minato-ku : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Miyagi : Site Reference ID/Investigator# 68736

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Morioka : Site Reference ID/Investigator# 79446

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nagakute : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Nagakute : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Nagasaki : Site Reference ID/Investigator# 79656

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nagoya : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Nagoya : Site Reference ID/Investigator# 79654

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nagoya : Site Reference ID/Investigator# 79653

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nagoya : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Neyagawa : Site Reference ID/Investigator# 79459

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nishinomiya :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Nishinomiya :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Nishinomiya : The Hospital of Hyogo College of Medicine Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Nishinomiya : Site Reference ID/Investigator# 79465

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Ohtsu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ohtsu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oita :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oita :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oita : Site Reference ID/Investigator# 79677

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Oita : Site Reference ID/Investigator# 79695

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Okayama : Site Reference ID/Investigator# 79479

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka : Osaka City University Hospital Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Osaka :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Osaka :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Osaka : Osaka City University Hospital Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Osaka : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Osaka : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Osaka : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Osaka : Site Reference ID/Investigator# 79448

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka : Site Reference ID/Investigator# 79464

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka : Site Reference ID/Investigator# 79449

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka : Osaka City University Hospital Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Osaka-City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Osaka-City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Osakasayama : Site Reference ID/Investigator# 79657

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Otsu : Shiga University of Medical Science Hospital Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Otsu : Site Reference ID/Investigator# 79673

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Saga : Site Reference ID/Investigator# 79674

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Saitama : Site Reference ID/Investigator# 79455

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Sakura :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sakura :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sakura : Site Reference ID/Investigator# 79476

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Sapporo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sapporo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sendai : National Hospital Organization Sendai Medical Center Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Sendai : National Hospital Organization Sendai Medlical Center Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Shinjuku :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Shinjuku-ku : Keio University Hospital Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Shinjuku-ku : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Shinjuku-ku : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Shinjyuku-ku : Social Insurance Chuo General Hospital Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Shinjyuku-ku : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Shunan : Site Reference ID/Investigator# 79453

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Suita : Site Reference ID/Investigator# 79634

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Takamatsu : Site Reference ID/Investigator# 79451

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Tokyo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tokyo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tokyo : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tokyo : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Tokyo : Site Reference ID/Investigator# 79699

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Tokyo : Site Reference ID/Investigator# 79641

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Toyohashi : Site Reference ID/Investigator# 81102

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Toyota : Site Reference ID/Investigator# 81100

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Yokkaichi :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Yokkaichi :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Yokkaichi : Site Reference ID/Investigator# 79458

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Yokohama : Site Reference ID/Investigator# 79473

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Korea, Republic of

Busan : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Daegu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Daegu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Daegu : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Daegu : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

View More »

Daegu : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Gyeonggi-Do :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Gyeonggi-Do :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Gyeonggi-do : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Pusan : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Pusan : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Seoul : Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Seoul :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Seoul :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Seoul : Severance Hospital, Yonsei University Health System Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul : Seoul National University Hospital,Division of Gastroenterology,Department of Internal Medicine Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul : Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul : ASAN Medical Center,Division of Gastroenterology,Department of Internal Medicine Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Seoul : Samsung seoul Hospital

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Seoul : Seoul National University Hospital

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Seoul : Seoul Asan Hospital

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Seoul : Seoul Saint Mary's Hospital

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Seoul : DaeHang Hospital

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Seoul : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Seoul : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Seoul : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Seoul : Severance Hospital, Yonsei University Health System Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Seoul : ASAN Medical Center,Division of Gastroenterology,Department of Internal Medicine Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Seoul : Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Wonju : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Wonju : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Latvia

Latvia : Latvia

A Study of TRK-170 for the Treatment of Crohn's Disease

Netherlands

Alkmaar : Site Reference ID/Investigator# 38181

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amersfoort : Site Reference ID/Investigator# 38179

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amsterdam :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Amsterdam :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Amsterdam : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

View More »

Amsterdam : VUMC

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Amsterdam : AMC

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Amsterdam : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Amsterdam : Site Reference ID/Investigator# 43042

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amsterdam : Pfizer Investigational Site Updated

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Amsterdam : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Amsterdam : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Amsterdam Zuidoost :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Groningen : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Groningen : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Leiden : Site Reference ID/Investigator# 38180

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Maastricht :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Maastricht :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Maastricht : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Maastricht : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Rotterdam :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rotterdam :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sittard-Geleen : Site Reference ID/Investigator# 93353

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

The Netherlands : The Netherlands

A Study of TRK-170 for the Treatment of Crohn's Disease

Utrecht : UMCU

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

New Zealand

Auckland :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Auckland :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Christchurch : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Christchurch :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Christchurch :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

View More »

Christchurch : University of Otago

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Christchurch : University of Otago

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Dunedin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Dunedin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Dunedin : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Grafton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Grafton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hamilton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hamilton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hamilton : Waikato Hospital

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Hamilton : Waikato Hospital

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Hastings :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hastings :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lower Hutt : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Lower Hutt : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Lower Hutt : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Milford : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Otahuhu, Auckland : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Otahuhu, Auckland : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Plenty :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Plenty :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tauranga. : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tauranga. : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Wellington : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Wellington :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Norway

Bergen : Department of Medicine, Haukeland University Hospital

Contrast Enhanced Ultrasonography (CEUS) of Patients With Crohn's Disease

Gjettum : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Gjettum : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Norway : Norway

A Study of TRK-170 for the Treatment of Crohn's Disease

Oslo : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

View More »

Rud : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Poland

Bydgoszcz :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bydgoszcz : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bydgoszcz : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Bydgoszczy : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Bydgoszczy : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

View More »

Czestochowa :

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Elblag :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Elblag :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Krakow :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Krakow :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Krakow : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Krakow : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Lodz :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lodz :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lodz : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Lublin : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Poland : Poland

A Study of TRK-170 for the Treatment of Crohn's Disease

Rzeszow : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Rzeszow : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Sopot : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Torun : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Warsaw : Site Reference ID/Investigator# 63364

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Warsaw : Site Reference ID/Investigator# 60903

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Warszawa :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Warszawa :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Warszawa : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Warszawa : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Warszawa : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Warszawa : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Wroclaw : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Wroclaw : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Wroclaw : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Wroclaw : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Portugal

Lisboa : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Porto : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Puerto Rico

San Juan : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Romania

Bucharest : Site Reference ID/Investigator# 69643

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Bucharest : Site Reference ID/Investigator# 69642

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Romania : Romania

A Study of TRK-170 for the Treatment of Crohn's Disease

Timisoara : Site Reference ID/Investigator# 69644

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Russian Federation

Ekaterinburg : 28

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Ekaterinburg : 13

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Kazan : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Kazan : 12

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Kazan : 16

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

View More »

Moscow :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Moscow :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Moscow : 11

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 5

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 25

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 8

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 24

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 14

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 9

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 7

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 31

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Nizhniy Novgorod :

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Nizhniy Novgorod : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Nizhniy Novgorod : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Novgorod : 23

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Novosibirsk :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Novosibirsk :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Orenburg : 20

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Orenburg : 21

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Orenburg : 29

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Rostov-on-Don : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Saint Petersburg : 6

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Saint Petersburg : 1

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Saint Petersburg : 3

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Saint Petersburg : 4

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Saint-Petersburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Samara : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Samara : 18

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Samara : 15

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Shakhty : 17

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

St. Petersburg : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

St. Petersburg : 19

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

St. Petersburg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

St.Petersburg : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Taganrog : 10

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Tolyatti : 26

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Ufa : 32

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Ufa : 22

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Ufa : 27

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Ulyanovsk : 30

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Yaroslavl : 2

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Serbia

Belgrade :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Belgrade :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Belgrade : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Belgrade : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Beograd :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

View More »

Serbica : Serbia

A Study of TRK-170 for the Treatment of Crohn's Disease

Slovakia

Bratislava : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Bratislava : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Bratislava : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Nitra : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Nitra : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

View More »

Nitra : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Nitra : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Nitra : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Nove Mesto nad Vahom : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Nove Mesto nad Vahom : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Nove Mesto nad Vahom : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Nove Mesto nad Vahom : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Presov : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Presov : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Ruzomberok :

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Trnava : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

South Africa

Bellville : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Cape Town :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Cape Town :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Cape Town Western Cape :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Claremont : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

View More »

Claremont : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Claremont : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Claremont : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Durban :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Durban :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Durban : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Durban : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Durban : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Durban : Parklands Medical Centre Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Observatory : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Panorama : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Pretoria :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pretoria :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Somerset West Western Cape :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Spain

Barcelona : Hospital Clinic de Barcelona Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Barcelona :

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Barcelona : Hospital Clinic de Barcelona

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Barcelona : Site Reference ID/Investigator# 62624

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Barcelona : Hospital Clinic de Barcelona Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

View More »

Cordoba : Hospital Universitario Reina Sofia

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Elche : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Elche : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fuenlabrada (Madrid) : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Fuenlabrada (Madrid) : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Huelva : Hospital Juan Ramon Jimenez

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Madrid :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Madrid : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Madrid : Hospital Clinico San Carlos

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : Hospital 12 de Octubre

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : Hospital Universitario La Paz

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : Hospital La Princesa

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Madrid : Site Reference ID/Investigator# 38185

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Madrid : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Madrid : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Majadahonda : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Majadahonda : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Pontevedra : Hospital de Montecelo

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Sabadell :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sabadell : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Sabadell (Barcelona) : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Santiago De Compostela :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Seville : Hospital Virgen del Rocio

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Valencia : Hospital Universitario La Fe

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Valencia : Hospital de Sagunto

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Zaragoza : Site Reference ID/Investigator# 38186

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Sweden

Gothenburg : Site Reference ID/Investigator# 39065

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lund : Site Reference ID/Investigator# 39064

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lund : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Lund : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Orebro : Site Reference ID/Investigator# 39066

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

View More »

Stockholm : Site Reference ID/Investigator# 39062

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Stockholm : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Stockholm : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Sweden : Sweden

A Study of TRK-170 for the Treatment of Crohn's Disease

Uppsala : Site Reference ID/Investigator# 39082

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Switzerland

Bern : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Bern : Site Reference ID/Investigator# 38192

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Zuerich : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Zuerich : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Zurich :

A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease

View More »

Zurich : Site Reference ID/Investigator# 38191

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Zürich : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Zürich : University Hospital

Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease

Taiwan

Taipei : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Turkey

Istanbul : Site Reference ID/Investigator# 93553

Improvement of Work Productivity and Quality of Life With Anti-Tumor Necrosis Factor (TNF) Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey.

Ukraine

Chernivtsi : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Dnipropetrovsk : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Dnipropetrovsk : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Donetsk : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Donetsk : Site Reference ID/Investigator# 68925

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

View More »

Donetsk : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Kharkiv : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Kharkiv : Site Reference ID/Investigator# 69266

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Kharkiv : Site Reference ID/Investigator# 70033

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Kharkiv : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Kyiv : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Lviv : Site Reference ID/Investigator# 68926

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Odesa : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Odesa : Site Reference ID/Investigator# 70034

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Poltava : Site Reference ID/Investigator# 68922

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Simferopol : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Simferopol : Site Reference ID/Investigator# 69265

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Ukraine : Ukraine

A Study of TRK-170 for the Treatment of Crohn's Disease

Vinnytsya : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Vinnytsya : Site Reference ID/Investigator# 68924

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Vinnytsya : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

United Kingdom

Birmingham :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Birmingham :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Brighton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Brighton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Bristol :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

View More »

Bristol :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Bristol : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bristol : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Cambridge : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Cambridge :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Cambridge :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Cardiff :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Coventry : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Edinburgh : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Edinburgh : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Exeter :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Glasgow : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Gloucester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Gloucester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Harrow :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Harrow : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Liverpool :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Liverpool :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Liverpool : Site Reference ID/Investigator# 43987

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

London : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

London :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

London :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

London : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Manchester : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Manchester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Manchester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Manchester : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Manchester : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Newcastle upon Tyne : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Newcastle-upon-Tyne : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Newcastle-upon-Tyne : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Norwich :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Norwich :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Norwich : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Nottingham : Research Site

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease

Nottinghamshirecc :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Nottinghamshirecc :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oxford :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oxford :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oxford : Site Reference ID/Investigator# 38196

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Oxford : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Oxford : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Salford : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Salford : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Shrewsbury :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Shropshire :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Southampton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Southampton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Southampton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Wolverhampton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Worthing : Worthing Hospital

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)